Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Naltrexone for the Treatment of Hormone-Refractory, Metastatic Breast Cancer

NCT00379197 is registered in ClinicalTrials.gov with Masonic Cancer Center, University of Minnesota as lead sponsor.

NCT NCT00379197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00379197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Naltrexone for the Treatment of Hormone-Refractory, Metastatic Breast Cancer
Lead sponsor
Masonic Cancer Center, University of Minnesota
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2006
Completion date
May 31, 2013
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer